Phase I, Open-label Study to Investigate Safety, Tolerability, PK, and PD of EMD 525797 After Single and Repeated Dosing at Different Dose Levels in Subjects With Hormone-resistant Prostate Cancer With Bone Mets and Progressive Disease Following Prior CTX.

Trial Profile

Phase I, Open-label Study to Investigate Safety, Tolerability, PK, and PD of EMD 525797 After Single and Repeated Dosing at Different Dose Levels in Subjects With Hormone-resistant Prostate Cancer With Bone Mets and Progressive Disease Following Prior CTX.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Abituzumab (Primary)
  • Indications Bone metastases; Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Nov 2012 New source identified and integrated (German Clinical Trials Register: DRKS00004067).
    • 23 Sep 2011 Results presented at the 2011 European Multidisciplinary Cancer Congress.
    • 06 May 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top